The test provides physicians with a personalized serogenetic profile for their patients. It is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn's patients.

Launched by Prometheus Laboratories Inc. (San Diego, CA, USA) the novel diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the Prometheus IBD Serology 7.

"The Prometheus Crohn's Prognostic allows clinicians to use serologic and genetic information in order to stratify patients relative to their risk of disease progression," said Marla Dubinsky, M.D., director of the IBD Pediatric Center at Cedars Sinai Medical center (Los Angeles, CA, USA). "This approach may help physicians develop a more individualized treatment plan for each patient and help them explain the risk/benefit ratio of these treatments to their patients and their families."

Crohn's disease is a chronic disorder that causes inflammation of the gastrointestinal tract. Symptoms of the disease include diarrhea, abdominal pain, fever, and rectal bleeding. Crohn's patients may require long-term medical care, including multiple hospitalizations, surgeries, and therapeutics. Crohn's disease is estimated to affect between 400,000 and 600,000 individuals in North America.

Related Links:
Prometheus Laboratories Inc.
Cedars Sinai Medical center